VERIGRAFT successfully completes the Eurostars project eBionerve to develop novel nerve grafts

VERIGRAFT just completed the three-year eBionerve project funded by Eurostars/Vinnova to bring novel tissue-engineered nerve grafts closer to a clinical reality. The grafts are intended for the regeneration of nerves and the restoration of nerve function in large numbers of patients with peripheral nerve damage.
There is a significant medical need for peripheral nerve regeneration, and eBionerve wants to develop a potential solution. The overall purpose of the project has been to make this new and unique technology as ready as possible for upcoming clinical trials and market approval. Process development, large animal studies, preparation for GMP production and preparation of regulatory documents are among the most important goals that have been successfully achieved. In other words, our project results lead to entirely new medical and commercial opportunities for the future.
The project has now taken a first-generation promising product candidate through a series of important preclinical and regulatory development steps. The single most important result is positive in vivo data in a relevant disease model in large animals. At the same time, knowledge and expertise in this field has been built up and important partnerships and networks have been started. This platform will be very valuable and will serve as a basis for continued research and development. This gives Europe’s industry a prominent role in one of Life Science’s most interesting future areas.
eBionerve is a multi-task project where the partners have collectively performed as many key-steps as possible on the way from promising in vitro data to a complete set of preclinical activities, all in order to make the technology ready for commercial-scale up and future clinical trials. The commercial partner VERIGRAFT has covered process development and all documentary and commercial tasks, while the academic partner and subcontractors have made various in vivo disease models possible. In focus for the collaboration has been to pave the way a first product-candidate.

VERIGRAFT is a partner in the Advanced Therapies Vision Driven Health Project

VERIGRAFT is proud to be a partner in the Advanced Therapies program under ’Vision Driven Health’.
The Advanced Therapies field is one of five recipients of funding under the program ’Vision Driven Health’, recently launched by the Swedish innovation agency Vinnova. Through “vision-driven innovation environments”, the program supports consortia of both public and private actors with necessary competencies to set ambitious but achievable long terms goals to meet important health challenges through system level change. The advanced therapies project vision is for “Sweden to become a world leader in development and implementation of advanced therapies by 2030”.
The Advanced Therapies Vision Driven Health project is coordinated by Research Institutes of Sweden (RISE) and begins with 17 partners from healthcare, industry, regulatory authorities, academia, and relevant institutions.

VERIGRAFT accepted as member in CAMP

VERIGRAFT is happy to announce that we have become members in CAMP (Centre for Advanced Medical Products), a newly-formed prestigious Swedish national center for advanced therapies.

Advanced therapies based on genes, cells or tissues (ATMPs) have great potential to generate completely new ways of treating or even curing diseases. The Center for Advanced Medical Products (CAMP) focuses on the science, technology and infrastructure required to implement ATMPs from laboratory to clinical practice. The center also addresses the systems and organizational challenges identified as obstacles to the development of the ATMP field in Sweden. Integration of preclinical, clinical, technical and other scientific areas, with commercialization skills, will accelerate research implementation, new patient treatments and industrial growth. The project will optimize cooperation between ATMP infrastructure and academy / healthcare activities as well as commercial preclinical and clinical R&D. This will facilitate further development and commercialization of ATMP and increase Sweden’s competitiveness in this area.

VERIGRAFT nominated for SwedenBIO Award 2018

Gothenburg May 16, 2018
We are proud to announce that VERIGRAFT has been nominated for the SwedenBIO Award 2018. The prize is awarded to a life-science company that has demonstrated accomplishments and achievements beyond the ordinary and contributed to a positive interest in the industry. SwedenBIO Award is the Swedish bioindustry’s own award. The jury consists of SwedenBIO’s Board and a representative of the price sponsor, the global life science investment fund HealthCap AB.
SwedenBIO is the national non-profit association for the life science industry in Sweden, with more than 230 members,

VERIGRAFT wins a major grant for the development of its novel P-TET production platform

Gothenburg, November 1, 2017

Research Institutes of Sweden (RISE) and VERIGRAFT today announce they have been granted support for a joint project with the title “Production Platform for Personalized Tissue-Engineered Transplants”. The project will be financed by Swedish governmental Vinnova with SEK 5M. The general aim of the project is to develop a tissue manufacturing platform to bring VERIGRAFT´s technology to a broader industrial application within regenerative medicine. Thereby the availability of transplantable organs and tissues will be dramatically increased.

“We are extremely pleased about having this project proposal granted, since it allows our tissue engineering platform to reach another level of industrialization. Together with our strong and committed partner RISE, adding synergistic technological skills to the program, our technology will be more widely applicable for a series of hitherto uncured severe diseases. This will certainly be a key project for the whole field of advanced therapies and regenerative medicine,” says Dr Petter Björquist, CEO of VERIGRAFT.

VERIGRAFT is a regenerative medicine company, located in Gothenburg, Sweden. The company generates personalized tissue-engineered transplants for use in regenerative medicine. The company’s unique technology platform turns donated allogeneic (“foreign”) tissue into an autologous (“personalized”) tissue and thus avoids transplant rejection and the need for life-long immunosuppression. Donated, allogeneic tissue is patient-individualized by a combination of DC (Decellularization) and RC (Reconditioning/Recellularization) processes. VERIGRAFT’s development pipeline comprises products in the areas of vascular regeneration and peripheral nerve repair.

RISE Research Institutes of Sweden is fully owned by the Swedish state. RISE supports all manner of innovative processes, and is instrumental in developing the future-proofing of products, technologies, and services. Through collaboration with academia, industry and the public sector, RISE contributes to the competitiveness of the Swedish business community on an international level.

Vinnova is a Swedish government agency working under the Ministry of Enterprise and Innovation and acts as the national contact agency for the EU Framework Program for R&D. Vinnova is also the Swedish government’s expert agency within the field of innovation policy. Vinnova was founded in January 2001, and about 200 people work in their offices in Stockholm and Brussels.